Literature DB >> 6363247

Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors.

G B McDonald, P Sharma, D E Matthews, H M Shulman, E D Thomas.   

Abstract

Venocclusive disease (VOD) of the liver, a fibrous obliteration of small hepatic venules, can be caused by chemoradiation therapy. We reviewed 255 consecutive patients undergoing bone marrow transplantation for malignancy during 1978 to 1980 in order to determine the incidence of VOD and the predisposing factors. Fifty-three of 255 patients met our criteria for VOD, for an incidence of 21%. Multivariate analysis showed that the most significant risk factors for VOD were age over 15, an underlying malignancy other than acute lymphocytic leukemia and hepatitis prior to transplantation. Patients with hepatitis had a 3.4-fold risk of developing VOD, as compared to patients with normal SGOT values (p = 0.0004). Hepatitis in this setting is probably of non-A, non-B viral etiology and represents a relative contraindication to marrow transplantation because of enhanced toxicity from conditioning chemoradiotherapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6363247     DOI: 10.1002/hep.1840040121

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  131 in total

Review 1.  [Thrombophilic states in intensive care medicine].

Authors:  L Engelmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2011-10-28       Impact factor: 0.840

2.  Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation.

Authors:  Takayoshi Tachibana; Masatsugu Tanaka; Hirotaka Takasaki; Ayumi Numata; Shin Fujisawa; Atsuo Maruta; Hiroshi Harada; Hiraku Mori; Yoshiaki Ishigatsubo; Heiwa Kanamori
Journal:  Int J Hematol       Date:  2011-12-02       Impact factor: 2.490

3.  Fatal hepatic sinusoidal obstruction syndrome in a child with primary CNS lymphoma during induction therapy.

Authors:  Shohei Yamamoto; Kousuke Akiyama; Nobuo Oyama; Mayumi Hayashi; Yoko Fujimoto; Hirokazu Ikeda; Keiichi Isoyama
Journal:  Int J Hematol       Date:  2012-06-27       Impact factor: 2.490

4.  Anicteric veno-occlusive disease after hematopoietic stem cell transplantation in children.

Authors:  J C Naples; M A Skeens; J Auletta; H Rangarajan; R Abu-Arja; E Horwitz; J Stanek; R S Bajwa
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

5.  Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.

Authors:  Brandon M Triplett; Hani I Kuttab; Guolian Kang; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-14       Impact factor: 5.742

6.  Role of Initiating Supportive Care Preceding Veno-occlusive Disease Diagnosis Following Allogeneic Hematopoietic Stem Cell Transplantation in Children.

Authors:  Patricia Rayner; Jessica L Spruit; Roland Chu; Maxim Yankelevich; Meret Henry; Yaddanapudi Ravindranath; Süreyya Savaşan
Journal:  J Pediatr Hematol Oncol       Date:  2019-08       Impact factor: 1.289

7.  Diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome of the liver: problems of interpretation.

Authors:  L Volin; R Niittyvuopio; J Heiskanen; V Lindström; A Nihtinen; L Sahlstedt; T Ruutu
Journal:  Bone Marrow Transplant       Date:  2016-09-26       Impact factor: 5.483

Review 8.  Vascular liver diseases.

Authors:  Laurie D DeLeve
Journal:  Curr Gastroenterol Rep       Date:  2003-02

9.  Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation.

Authors:  In-Wha Kim; Hwi-yeol Yun; Boyoon Choi; Nayoung Han; Myeong Gyu Kim; Seonyang Park; Jung Mi Oh
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

10.  Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.

Authors:  Andrew R Rezvani; Jeannine S McCune; Barry E Storer; Ami Batchelder; Aiko Kida; H Joachim Deeg; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-10       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.